Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Idiopathic Pulmonary Fibrosis Management Market Snapshot (2023 to 2033)

The global idiopathic pulmonary fibrosis management market is expected to garner a market value of US$ 3145 Million in 2023 and is expected to accumulate a market value of US$ 3649.90 Million by registering a CAGR of 1.5% in the forecast period 2023 to 2033. The growth of the idiopathic pulmonary fibrosis management market can be attributed to the increasing prevalence of the ailment in males across the globe. The market for idiopathic pulmonary fibrosis management registered a CAGR of 1% in the historical period 2018 to 2022

Idiopathic pulmonary fibrosis (IPF) is a lung disorder with scarring of the lungs from an unknown cause. It is one of the most aggressive forms of idiopathic interstitial pneumonia (IIPs). The majority of patients are male, and the risk of IPF for someone aged 75 years is eight times that of someone aged 45 to 54 years. It is reported that without treatment, the median survival in patients with IPF is 2 to 4 years after diagnosis. Males are more predominantly affected highly with IPF than females. In 2021, there were 121,389 males and 73,488 females affected by IPF in the 7MM.

There are two antifibrotic agents approved for use in IPF. These are pirfenidone and nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of IPF with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.

Report Attribute Details
Expected Market Value (2023) US$ 3145 Million
Anticipated Forecast Value (2033) US$ 3649.90 Million
Projected Growth Rate (2023 to 2033) 1.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Idiopathic Pulmonary Fibrosis Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights - the market for Idiopathic pulmonary fibrosis management reflected a value of 1% during the historical period, 2018 to 2022.

The total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was 194,878 cases in 2021. Gastrointestinal side effects are the most common reason for discontinuing both drugs. According to survey reports, most European physicians are either unaware of these antifibrotic drugs or believe in the wait-and-watch strategies during the progression of IPF. It was found that only 71% of mild IPF-diagnosed patients, 41% of moderate IPF-diagnosed patients, and around 60% of severe IPF-diagnosed patients receive treatment in European counties.

Over the years, some drugs have been investigated to treat IPF cases. Drug molecules such as Pamrevlumab, PRM-151, and Inhaled Treprostinil are in Phase III and have shown positive results in previous clinical studies. In addition to this, some candidates are in Phase II and early stages. Thus, the market for Idiopathic pulmonary fibrosis management is expected to register a CAGR of 1.5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Idiopathic Pulmonary Fibrosis Management Market?

Increasing prevalence of Idiopathic pulmonary fibrosis in middle-aged men boosting the market growth

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect middle to aged and older adults. It affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis), which increases irreversibly over time.

If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).

It is a form of interstitial lung disease, primarily involving the interstitium (the tissue and space around the air sacs of the lungs) and not directly affecting the airways or blood vessels. Many other kinds of interstitial lung disease can also cause inflammation and/or fibrosis, and these are treated differently.

Availability of various diagnostic treatments spurring the growth of Idiopathic pulmonary fibrosis management

There are several diagnostic tools available and the consensus guidelines have been well-defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity.

When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like XtoRays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.

Careful evaluation of clinical, laboratory, Xtoray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with an interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathology data.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Idiopathic Pulmonary Fibrosis Treatment

The therapeutic approach to Idiopathic Pulmonary Fibrosis involves both non-pharmacological and pharmacological strategies. The goal of the treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations, and prolong survival. There are two anti-fibrotic agents ESBRIET (Roche) and OFEV (Boehringer Ingelheim) approved for use in IPF. Both drugs are known to slow the disease progression but do not significantly impact mortality.

What are the Challenges Faced by the Idiopathic Pulmonary Fibrosis Management Market?

Lack of awareness and high cost of treatment affecting the market growth

Difficulty in diagnosis is a key factor hindering the growth of the market. As IPF often mimics other lung diseases, making it difficult to diagnose. This can lead to delayed treatment and a poorer prognosis. Furthermore, limited treatment options and no assurance of results are derailing the growth of the market.

In addition, lack of awareness of IPF as it is a rare disease. This can make it difficult for patients to find doctors who are familiar with the disease and can lead to a delay in diagnosis and treatment. Moreover, the high cost of treatment is a burden for patients and their families. All these factors are creating obstacles to the growth of the market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Region-Wise Insights

Accelerated Drug Approvals in North America Creating Lucrative Opportunities for Idiopathic Pulmonary Fibrosis Management Market?

High market penetration and increasing prices of the drugs are other factors driving the growth of the market

The highest diagnosed prevalent cases of IPF were accounted for by the USA in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population. Owing to high market penetration and increasing prices of the drugs are other factors driving the growth of the market. The market is growing rapidly due to accelerated approvals of two drugs in the United States of America. Moreover, the increasing prevalence of IPF is one of the major factors anticipated to boost the market.

Manufacturers offer various programs to improve access among patients. For instance, F. Hoffman La-Roche, Ltd (Genentech) offers Genentech Access to Care Foundation and Esbriet Co-Pay Card Program that covers out-of-pocket expenses and provides Esbriet free of charge for certain household income thresholds. Boehringer Ingelheim offers similar free access and co-pay assistance programs. Thus, North America is expected to possess a 45% market share for the Idiopathic pulmonary fibrosis management market in 2023.

Higher Number of Individuals Suffering from Idiopathic Pulmonary Fibrosis Boosting Market Growth in Europe?

Launch of innovative medications supporting idiopathic pulmonary fibrosis management market growth in Europe

Europe was estimated to be the second-largest market in 2022 owing to the increasing prevalence of IPF. For instance, according to the European Idiopathic Pulmonary Fibrosis Foundation, 30,000 to 35,000 new cases of IPF are diagnosed every year. Moreover, between 80,000 to 111,000 people are living with IPF in Europe. The average life expectancy of patients diagnosed with IPF is 2-5 years.

Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population. In addition, improved healthcare infrastructure along with the availability of innovative medications is expected to drive the growth of the market. Thus, Europe is expected to hold a 40% market share of the Idiopathic pulmonary fibrosis management market in 2023.

Category-Wise Insights

Availability of Wide Range of Medication Making Retail Pharmacies Favorable for Idiopathic Pulmonary Fibrosis Management Market?

Easy purchase of multiple medicines increasing the popularity of retail pharmacies

The availability of both prescription and over-the-counter drugs in retail pharmacies is driving growth in the pulmonary fibrosis treatment market and is expected to continue doing so in the future. This, in turn, makes it convenient for consumers to fill multiple prescriptions and purchase other healthcare products all in one place.

This increase in convenience and access to healthcare services is likely a major factor in the growing popularity of retail pharmacies. Thus, retail pharmacies are expected to possess a 40% market share of the Idiopathic pulmonary fibrosis management market in 2023.

Market Competition

Key players in the idiopathic pulmonary fibrosis management market are Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova Inc, Bristol Myers Squibb Company, Galapagos NV, HoffmanntoLa Roche AG, Neopharm Group, Galecto Biotech, Pfizer Inc, Johnson & Johnson Services, Inc, AstraZeneca

  • Boehringer Ingelheim GMBH, a key player in the idiopathic pulmonary fibrosis management market is working on a combination therapy of nintedanib and pirfenidone, which is currently under clinical trial. They also have a pipeline of potential new treatment options for IPF that are currently in preclinical or early-stage development. In addition, Boehringer Ingelheim GMBH is also actively involved in clinical trials to further explore the safety and efficacy of their drugs in IPF treatment.
  • Pfizer another key player in the idiopathic pulmonary fibrosis management market is actively involved in clinical trials to further explore the safety and efficacy of their drugs in IPF treatment. The company is also working on the development of a therapy that targets the underlying causes of IPF by modulating the immune system, which is still under research.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 3145 Million
Market Value in 2033 US$ 3649.90 Million
Growth Rate CAGR of 1.5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Drug Class
  • Treatment
  • Route of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Argentina
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASIAN
  • GCC Countries
  • South Africa
Key Companies Profiled
  • Boehringer Ingelheim GMBH
  • Biogen
  • Novartis AG
  • Medicinova Inc
  • Bristol Myers Squibb Company
  • Galapagos NV
  • Hoffmann-La Roche AG
  • Neopharm Group
  • Galecto Biotech
  • Pfizer Inc
  • Johnson & Johnson Services, Inc
  • AstraZeneca
Customization Available Upon Request

Key Segments Profiled in the Idiopathic Pulmonary Fibrosis Management Industry Survey

Drug Class:

  • Pirfenidone
  • Nintedanib
  • Interferon Gammato1b
  • Others

Treatment:

  • Oxygen Therapy
  • Lung Transplant
  • Others

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

Where is the Higher Demand for Idiopathic Pulmonary Fibrosis Management?

The United States generated 40% of the global demand in 2022.

Which Regional Market May Witness Higher Growth?

The Asia Pacific market is expected to grow at 9.4% through 2033.

Which is the Preferred Material in the Market?

The small molecule drugs segment contributes 60% of total production.

Which Product Type is in Higher Demand?

The oral segment holds 55% of the global market share.

How the Idiopathic Pulmonary Fibrosis Management market developed in the Past?

From 2018 to 2022, the global market exhibited a CAGR of 1%.

Table of Content

1. Executive Summary | Idiopathic Pulmonary Fibrosis Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Pirfenidone

        5.3.2. Nintedanib

        5.3.3. Interferon Gamma-1b

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        6.3.1. Oxygen Therapy

        6.3.2. Lung Transplant

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        7.3.1. Oral

        7.3.2. Injectable

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Drug Class

        10.2.3. By Treatment

        10.2.4. By Route of Administration

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Treatment

        10.3.4. By Route of Administration

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Class

        11.2.3. By Treatment

        11.2.4. By Route of Administration

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Treatment

        11.3.4. By Route of Administration

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. UK

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Class

        12.2.3. By Treatment

        12.2.4. By Route of Administration

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Treatment

        12.3.4. By Route of Administration

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug Class

        13.2.3. By Treatment

        13.2.4. By Route of Administration

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Treatment

        13.3.4. By Route of Administration

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Class

        14.2.3. By Treatment

        14.2.4. By Route of Administration

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Treatment

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Drug Class

        15.2.3. By Treatment

        15.2.4. By Route of Administration

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Treatment

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug Class

        16.2.3. By Treatment

        16.2.4. By Route of Administration

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Class

        16.3.3. By Treatment

        16.3.4. By Route of Administration

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Class

            17.1.2.2. By Treatment

            17.1.2.3. By Route of Administration

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Class

            17.2.2.2. By Treatment

            17.2.2.3. By Route of Administration

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Class

            17.3.2.2. By Treatment

            17.3.2.3. By Route of Administration

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Class

            17.4.2.2. By Treatment

            17.4.2.3. By Route of Administration

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Class

            17.5.2.2. By Treatment

            17.5.2.3. By Route of Administration

            17.5.2.4. By Distribution Channel

    17.6. UK

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Class

            17.6.2.2. By Treatment

            17.6.2.3. By Route of Administration

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Class

            17.7.2.2. By Treatment

            17.7.2.3. By Route of Administration

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Class

            17.8.2.2. By Treatment

            17.8.2.3. By Route of Administration

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Class

            17.9.2.2. By Treatment

            17.9.2.3. By Route of Administration

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Class

            17.10.2.2. By Treatment

            17.10.2.3. By Route of Administration

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Class

            17.11.2.2. By Treatment

            17.11.2.3. By Route of Administration

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Class

            17.12.2.2. By Treatment

            17.12.2.3. By Route of Administration

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Class

            17.13.2.2. By Treatment

            17.13.2.3. By Route of Administration

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Class

            17.14.2.2. By Treatment

            17.14.2.3. By Route of Administration

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Class

            17.15.2.2. By Treatment

            17.15.2.3. By Route of Administration

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Class

            17.16.2.2. By Treatment

            17.16.2.3. By Route of Administration

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Class

            17.17.2.2. By Treatment

            17.17.2.3. By Route of Administration

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Class

            17.18.2.2. By Treatment

            17.18.2.3. By Route of Administration

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Class

            17.19.2.2. By Treatment

            17.19.2.3. By Route of Administration

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Class

            17.20.2.2. By Treatment

            17.20.2.3. By Route of Administration

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug Class

            17.21.2.2. By Treatment

            17.21.2.3. By Route of Administration

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Class

        18.3.3. By Treatment

        18.3.4. By Route of Administration

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Boehringer Ingelheim GMBH

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Biogen

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Novartis AG

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Medicinova Inc.

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Bristol-Myers Squibb Company

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Galapagos NV

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Hoffmann-La Roche AG

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Neopharm Group

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Galecto Biotech

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Pfizer Inc.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Johnson & Johnson Services, Inc.

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. AstraZeneca

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Radiation-Induced Fibrosis Treatment Market

Published : June 2023

Healthcare

Progressive Pulmonary Fibrosis (PPF) Treatment Market

Published : January 2023

Healthcare

Myelofibrosis (MF) Treatment Market

Published : December 2022

Healthcare

Cystic Fibrosis Therapeutics Market

Published : December 2022

Explore Healthcare Insights

View Reports

Idiopathic Pulmonary Fibrosis Management Market